Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 3 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Histiocytic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 81 Specimen Handling 80 Cyclophosphamide 72 pembrolizumab 61 Nivolumab 53 Radiotherapy 52 fludarabine 43 Cisplatin 42 Biopsy 40 Carboplatin 38 Standard of Care 35 Dexamethasone 31 Radiation 30 Bevacizumab 30 Rituximab 29 Surveys and Questionnaires 27 Radiosurgery 26 Doxorubicin 26 Temozolomide 25 Gemcitabine 25 Cytarabine 25 Blood Specimen Collection 25 venetoclax 24 Practice Guidelines as Topic 24 Paclitaxel 24 fludarabine phosphate 23 Ipilimumab 21 atezolizumab 20 Vincristine 20 Interviews as Topic 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × ulixertinib × 30 days × Clear all

NCT06411821 2026-05-28

Ulixertinib in People With Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting

Histiocytic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡